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Cleveland, OH 44195. E-mail: kleinr3@ccf.orgOn June 13, 2013, the Supreme Court of the United States in
Association for Molecular Pathology v Myriad Genetics, Inc.,
unanimously ruled that naturally occurring DNA sequences
cannot be patented.1 The court speciﬁcally held that the DNA
sequences of the humanBRCA1 andBRCA2 genes are products
of nature, rendering invalid the patents claiming these se-
quences. However, the court did rule that, in contrast to natural
DNA sequences, nonnaturally occurring cDNA meets this
threshold test of patent eligibility.Onbehalf of the court, Justice
Clarence Thomas wrote, “cDNA is not a ‘product of nature’.
except insofar as very short series of DNAmay have no introns
to remove... In that situation a short strand may be indistin-
guishable from natural DNA.”1 By removing natural gene,
primer, and probe sequences from the realm of patent-eligible
subject matter, the court eliminated a substantial barrier to
clinical testing for disease-related variation in patented genes.
The Association for Molecular Pathology (AMP), the
lead plaintiff in the case, extolled the ruling as a “critical and
right decision” for patients, medicine, and science (http://
www.prnewswire.com/news-releases/amp-celebrates-scotus-
decision-on-amp-v-myriad-case-211436871.html, last ac-
cessed June 13, 2013), whereas the coplaintiff, the College
of American Pathologists, emphasized that women will no
longer have to “trust one provider” of BRCA1 and BRCA2
test services (http://www.prnewswire.com/news-releases/
patients-win-in-supreme-court-gene-patent-decision-211418
231.html, last accessed June 13, 2013). The American
Medical Association also weighed in, stating, “The U.S.
Supreme Court’s unanimous rejection of patenting human
genes is a clear victory for patients that will expand medical
discovery and preserve access to innovative diagnosis
and treatment options” (http://www.ama-assn.org/ama/pub/
news/news/2013/2013-06-13-end-to-human-gene-patents.page,
last accessed June 13, 2013). By contrast, the Biotechnology
Industry Association, an opponent of the suit, lamented that
the decision “represents a troubling departure from decadesCopyright ª 2013 American Society for Investigative Pathology
and the Association for Molecular Pathology.
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http://dx.doi.org/10.1016/j.jmoldx.2013.09.002of judicial and Patent and Trademark Ofﬁce precedent” that
“could unnecessarily create business uncertainty for a
broader range of biotechnology inventions” (http://www.
bio.org/media/press-release/statement-us-supreme-court-
review-isolated-dna-patents, last accessed June 13, 2013).
The Harm of Gene Patents
Gene patents have proved highly controversial in clinical
diagnostics. Although many in industry and the patent bar
argue that these patents promote discovery and encourage the
production of novel diagnostic tests, patient and consumer
organizations, pathologists, geneticists, and other laboratory
professionals contend that such patents increase costs, reduce
patient access and choices, decrease innovation, inhibit
research, and foster the development of proprietary databases
of medically important genetic ﬁndings.2e4
Many providers have discontinued or have been prevented
from providing molecular pathology testing for several he-
reditary diseases, examples of which include inherited breast
and ovarian cancer, Duchenne muscular dystrophy, spino-
cerebellar ataxias, and long QT syndrome.5e7 Gene patents
have prevented laboratories from testing for the FLT3 inter-
nal tandem duplication mutation in acute myeloid leukemia
and the JAK2 V617F mutation in myeloproliferative neo-
plasms. Congressmen Xavier Becarra (D-CA) and David
Guest EditorialWeldon (R-FL), in 2007, cosponsored HR 977: Genomic
Research and Accessibility Act (110th Congress, 2007 to
2009, http://www.govtrack.us/congress/bills/110/hr977, in-
troduced February 9, 2007) in an attempt to eliminate gene
patents, but this legislationwas restricted to future genepatents
and was never enacted into law. Hence, the sole recourse for
patients and practitioners appeared to be through the courts.
Therefore, when the American Civil Liberties Union and the
Public Patent Foundation asked AMP to sign on as a plaintiff
in a suit to invalidate Myriad Genetics’ BRCA1 and BRCA2
patents, the society leadership felt compelled to join the case.
TheSupremeCourt’s decision inwhat ultimately came to be
known as AMP v Myriad was strongly worded and broadly
written. The court acknowledged Myriad’s important contri-
butions in identifying the precise chromosomal locations and
sequences of BRCA1 and BRCA2 but recognized that these
discoveries were not patent-eligible inventions. “In this case
. Myriad did not create anything,” wrote Justice Thomas.1
“To be sure, it found an important and useful gene, but sepa-
rating that gene from its surrounding genetic material is not an
act of invention.”The court also recognized that ampliﬁcation,
sequencing, and the other techniques that Myriad applied in
isolating the genes were in routine use at the time. “Had
Myriad created an innovative method of manipulating genes
.” the court proclaimed, “it could possibly have sought a
method patent. But the processes used by Myriad ‘were well
understood, widely used, and fairly uniform insofar as any
scientist engaged in the search for a gene would likely have
used a similar approach.’”Moreover, the court clearly directed
its decision toward negation of genetic testing monopolies,
writing, “But isolation is necessary to conduct genetic testing,
andMyriadwas not the only entity to offer BRCA testing after
it discovered the genes. The University of Pennsylvania’s
Genetic Diagnostic Laboratory (GDL) and others provided
genetic testing services to women.”1
Prometheus as Forerunner
AMP v Myriad must be read side by side with a related Su-
preme Court decision, Mayo Collaborative Services v Pro-
metheus Laboratories, Inc.8 Although AMP held that patents
cannot be granted on natural DNA sequences, Mayo
addressed the patent eligibility of natural relationships be-
tween biomarkers and clinical phenotypes. In Mayo, Prome-
theus Laboratories sued Mayo Clinic for infringement of two
patents covering the postadministration correlation of blood
levels of thiopurine metabolites with drug efﬁcacy and
adverse effects. Prometheus’ patents framed these associa-
tions as processes that included thiopurine administration,
metabolite level determination, and recognition of the po-
tential need to alter the drug dose. The Supreme Court
unanimously ruled that Prometheus’ patents were invalid.
Prometheus maintained that it patented applications of bio-
logical relationships rather than the relationships themselves.
However, the Supreme Court disagreed. To patent an appli-
cation of a natural law, the court expounded, other elements732must be added to the law that are sufﬁcient to ensure that the
patent is “signiﬁcantly more than a patent on the natural law
itself.”8 Moreover, appending routine steps to a natural law
cannot convert it into a patentable process. Thus, Justice Ste-
phen Breyer, on behalf of the court, wrote, “If a law of nature is
not patentable, then neither is a process of reciting a law of
nature unless that process has additional features that provide
practical assurance that the process is more than a drafting
effort designed to monopolize the law of nature itself.”8
The patents at issue inMayo and AMP represent two sides of
the gene patent coin (ie, variant-phenotype associations inMayo
and gene sequences in AMP). Fundamentally, however, both
patent types are intended to effect monopolies on testing for
associations of genetic variants with clinical phenotypes. The
Supreme Court explicitly linked the two cases together by reit-
erating the following words from Mayo in its AMP decision,
“Laws of nature, natural phenomena, and abstract ideas are not
patentable. Rather, ‘they are the basic tools of scientiﬁc and
technological work’ that lie beyond the domain of patent pro-
tection.. without this exception there would be considerable
danger that the grant of patents would ‘tie up’ the use of such
tools and thereby ‘inhibit future innovationpremisedon them.’”1
The Future of Personalized Medicine
Together, AMP and Mayo appear to have brought an end to
patent-based monopolization of testing for human gene muta-
tions. These monumental decisions could not have come at a
more propitious time. We presently stand at the cusp of the
clinical adoption of large-scale gene sequencing, which prom-
ises to revolutionize the diagnosis, treatment, and prevention of
disease. AMP andMayowere critical for ensuring the universal
rights of patients and providers to access the information con-
tained within our genomes. The Supreme Court has, thereby,
changed history, profoundly encouraging the advancement,
development, and implementation of personalized medicine.
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